

JOURNAL OF MEDICINAL CHEMISTRY

© Copyright 1995 by the American Chemical Society

Volume 38, Number 8

April 14, 1995

Communications to the Editor

The C-32 Triacetyl-L-rhamnose Derivative of Ascomycin: A Potent, Orally Active Macrolactone Immunosuppressant

Kevin Koch,^{*,†} Michael F. Newborg,[‡]
Douglas C. Hanson,[‡] Kelvin Cooper,[†]
Richard M. Shepard,[‡] Michael L. Biehl,[§]
Michael S. Biggers,[†] Mukesh Ramchandani,[†]
Gary Schulte,^{||} Jeffrey R. Snyder,[‡]
Richard A. Ferraina,[‡] Carol Donovan,[‡]
Mark A. Guadliana,^{||} Gloria J. Kostek,^{||}
Susan H. Cole,[‡] Maureen J. Connolly,[‡]
Perry S. Sawyer,[‡] Ting-Po I,[#] Lawrence W. Blocker,[#]
Bruno M. Meiser,[¶] and Lawrence S. Melvin[†]

Central Research Division, Pfizer Inc.,
Groton, Connecticut 06340, and Department of
Cardiac Surgery, University of Munich, Germany

Received November 14, 1994

Immunosuppressive drugs have been used for the prevention of organ transplant rejection and to some extent for the treatment of severe autoimmune disease for many years. A major advance was made with the introduction of cyclosporin A (CsA).¹ This drug acts primarily on thymus-derived lymphocytes or T cells, which are the major cells in the immune system responsible for mediating allograft rejection.² T cells also mediate the pathology of various autoimmune diseases,³ and CsA has been used on an experimental basis to treat some of these conditions. Therapeutic effects have been observed in rheumatoid arthritis, psoriasis, Type I diabetes, and uveitis among others.⁴

Even though CsA has been used with remarkable success, it has many liabilities. Renal toxicity⁵ is dose-limiting and includes an acute and reversible, as well as a chronic and irreversible, component. This toxicity results in histological damage to renal tubules in

humans⁶ and other species. Additional dose-limiting conditions include hypertension, hirsutism, and tremors.⁷ The combination of a narrow therapeutic index coupled with variable pharmacokinetics has driven the search for better-tolerated immunosuppressants. One of the most promising new compounds is (tacrolimus, FK-506), a macrolactone immunosuppressant identified in 1987.⁸ Although initially described as not only more potent but also less toxic than CsA, these safety claims have been revised substantially. Tacrolimus, while somewhat more efficacious in liver transplantation, is similarly nephrotoxic and also has significantly greater neurologic side effects ranging from tremor to coma.⁹ Nevertheless, tacrolimus has been successfully utilized in patients who are unresponsive to CsA.¹⁰ Given this background, a better-tolerated immune suppressant with equivalent efficacy should not only replace CsA and tacrolimus but could also be employed beyond transplantation to treat severe forms of autoimmune disease, thus satisfying an important medical need.

The mode of action of these potent immunosuppressive drugs has been the topic of intense study over the past few years.¹¹ Although the structure of tacrolimus and CsA are very different in nature (Chart 1), their pharmacology is in many ways comparable. Each compound inhibits lymphokine (IL-2, IL-3, IL-4, GM-CSF, TNF α , IFN γ) production through blockade of Ca²⁺-dependent signal transduction pathways.¹² Initial work showed that these compounds interacted with specific *cis-trans*-prolyl isomerases (CsA with cyclophilin and tacrolimus with FKBP-12). Subsequently, it was observed that the complex of CsA-cyclophilin and the complex of tacrolimus-FKBP inhibited the function of the ubiquitous Ca²⁺ calmodulin-dependent phosphatase, calcineurin A, in human T cells.¹³ The current hypothesis is that a dephosphorylation event mediated by calcineurin is required for the translocation of a component of the IL-2 transcription factor, NF-AT, from the cytoplasm to the nucleus prior to gene transcription¹⁴ and that these drug complexes inhibit this dephosphorylation event. This model explains some of the biological effects of these immunosuppressants, but differences exist between CsA and tacrolimus,¹⁵ which may reflect different cellular targets (mast cells, macrophages,

[†] Department of Medicinal Chemistry.

[‡] Department of Cancer, Immunology and Infectious Diseases.

[§] Department of Drug Safety Evaluation.


^{||} Department of Drug Metabolism.

[#] Department of Natural Products Research.

[¶] Department of Bioprocess Research and Development.

[¶] University of Munich, Germany.


Chart 1



endothelial cells), drug tissue distribution, or immunophilin subtypes with differential cellular distributions.¹⁶

The key issue regarding the evaluation of a CsA or a tacrolimus-like molecule is not the efficacy of the drug, since this mechanistic class of compound has proven to be highly successful in clinical transplantation but rather toleration of the drug.¹⁷ With this thought in mind, we undertook a research program targeted at producing a potent, selective, and better-tolerated immunosuppressant based on the macrocyclic lactone, FK-520 (**3**, ascomycin), an analog of tacrolimus (Chart 1). Among the variety of approaches that were considered, one that could moderate the toxic effects of **3** would be to influence the tissue distribution of this class of compounds by introducing basic, acidic, lipophilic, or water-soluble moieties. Modifications at the cyclohexane unit of **3** were initially chosen because this group interacted with an external surface of the FK-binding protein, it was not directly involved with binding to calcineurin, and the C-32 hydroxyl group was readily functionalized with electrophilic agents. One novel method to obtain a diverse group of compounds at this position might be through glycosylation of the C-32 hydroxyl group with an appropriately substituted carbohydrate unit. Carbohydrates have a broad role in biological systems¹⁸ and have recently been reported to be essential in cellular trafficking, viral infectivity, and immunological regulation.¹⁹ These analogs would not only have different physical properties than **3** but might also distribute *in vivo* in a targeted manner and thereby show an increased therapeutic index. Carbohydrates were chosen on the basis of synthetic accessibility and the potential for lectins on lymphocytes to recognize unique sugar residues. Of particular interest was the report that receptors on human lymphocytes existed which had specificity for L-rhamnose.²⁰ A

Scheme 1



number of laboratories have research efforts directed toward the identification of macrocyclic immunosuppressants based on the skeleton of tacrolimus.²¹ In this communication we describe the novel, potent IL-2 biosynthesis inhibitor, **1** (CP-123,369) (Scheme 1), that contains a triacetyl-L-rhamnose sugar on the C-32 position of **3**. This compound is the first reported macrolactone-based molecule to possess a favorable therapeutic index relative to neurologic side effects (plasma drug concentration and dose) when compared to tacrolimus in 14–21 day rodent toxicology studies.

The synthesis of compound **1** is shown in Scheme 1. L-Rhamnose is treated with 48% hydrobromic acid and acetic anhydride in acetic acid to afford the triacetyl-L-rhamnosyl bromide **4** as a yellow oil which is used without purification.²² To a solution of **3**,²³ in methylene chloride at 0 °C, was added silver carbonate, catalytic silver trifluoromethane sulfonate, and 4-Å molecular sieves. Bromide **4** was then added dropwise and the mixture stirred at 22 °C for 4–8 h to provide the crude glycosylated product. Purification was accomplished by chromatography over silica gel followed by reverse-phase chromatography using C18 silica gel and then recrystallization from cyclohexane:isopropyl ether to give a 17% overall yield of **1**. Assignment as the α anomer off the C-32 position of **3** was made by NMR analysis and confirmed by X-ray crystal structure.

Compound **1** is a potent inhibitor of human T-lymphocyte proliferation and lymphokine production. Treatment of human T cells with phorbol myristate acetate (PMA, 5 ng/mL) and ionomycin (125 ng/mL)²⁴ activates calcium-dependent T-cell proliferation as measured by [³H]thymidine incorporation. In this system, **1** inhibits the proliferative response with an IC₅₀ = 10.4 nM (*n* = 3). Compound **1** was also effective in blocking production of the T-cell growth factor, IL-2. T cell production of IL-2 using PMA (10 ng/mL) and phytohemagglutinin (PHA, 2 μ g/mL) stimulation was blocked by **1** with an IC₅₀ = 11.0 nM (*n* = 10).²⁴

Two methods were used to assess the *in vivo* activity of this molecule. The rat adjuvant-induced arthritis

Table 1. Comparative Pharmacology of Immunosuppressive Agents

	1 CsA FK-506		
<i>in vitro</i> (IC ₅₀) ^a			
human IL-2 (nM)	11.0	8.1	0.9
human T-cell proliferation (nM)	10.4	13.7	0.5
<i>in vivo</i>			
rat heart ^b transplantation: est. ED ₁₀₀ (mg/kg)	30	15	3-5
rat adjuvant arthritis: ^c ED ₅₀ (mg/kg)			
1° lesion	10	3.4	1.9
2° lesion	2.3	0.7	0.6

^a *In vitro* IC₅₀ determinations were performed as described in ref 24. ^b Brown Norway rat hearts into Lewis rats heterotopically ($n = 8$). ED₁₀₀ = no rejection. ^c Arthritis was induced in Lewis rats ($n = 24$) as described in ref 25.

model²⁵ was used to evaluate the oral activity of **1** in this model of autoimmune disease. In this study, Lewis rats were treated daily by the oral route (10:20:70 cremophor/ethanol/water vehicle) starting the day before injection of a small volume of mycobacteria in oil into the right rear footpad. After 16 days the volumes of the injected (primary lesion, acute inflammation) and uninjected (secondary lesion, chronic systemic inflammation) footpads were measured. ED₅₀ values for the primary and secondary lesions were 10.6 and 2.3 mg/kg, respectively. Plasma levels of **3** generated by the cleavage of the rhamnase sugar from **1** were less than 0.2 ng/mL as measured by HPLC/MS. Compound **1** was also efficacious in a rat heterotopic heart transplant model.²⁶ In this model, hearts from Brown Norway rats were surgically implanted into the peritoneal cavity of histoincompatible Lewis rats. Rejection was assessed by palpating the transplanted heart and grading the strength of beating on a scale of 0-4, with 0 indicating no beat and therefore complete rejection and 4 indicating that a heart was beating as strongly as the host organ. Animals ($n = 8$) treated orally from days 0 to 50 with 30 mg/kg of **1** did not reject their grafts after surgery and displayed scores of 3-4 at day 50.

Both CsA and tacrolimus were evaluated in similar experimental protocols. By comparison (Table 1), compound **1** has similar *in vitro* and *in vivo* potency as CsA and is about 10-fold less potent than tacrolimus. Since tacrolimus is currently administered at 0.05-0.15 mg/kg/day in humans, we believed that compound **1** was sufficiently potent for clinical evaluation if an advantage in therapeutic index could be demonstrated over tacrolimus.

In order to determine the therapeutic index of compound **1** in relation to tacrolimus, Sprague-Dawley rats were orally gavaged, daily with **1** (30/100/300 mg/kg) or tacrolimus (3/6/12/24 mg/kg) for a period of 14-21 days or until neurotoxicity was observed. Drug plasma levels were determined on the last day of dosing (steady state) at 1, 2, 4, 8, and 24 h. Compound **1** and tacrolimus are both extensively metabolized in rats; however, the major metabolites (monodeacetylation for **1** and O-demethylation for tacrolimus) are 10-100 times less potent than the parent drugs. The toxic doses and associated plasma C_{max} values from the toleration studies were then compared to the doses and plasma C_{max} values required to show ED₅₀ activity in the primary lesion of the rat adjuvant arthritis model (see Table 2). Compound **1** at an ED₅₀ dose of 10 mg/kg gave a C_{max} plasma concentration of 254 ng/mL ($n = 6$). At the highest dose tested of 300 mg/kg po, with the related plasma C_{max} of 2908 ng/mL ($n = 10$), no toxicologic side

Table 2. Comparative Therapeutic Indexes of **1** and tacrolimus

	1	tacrolimus
ED ₅₀ dose (mg/kg)	10	2
ED ₅₀ C _{max} (ng/mL)	254	24
MND (14-21 day) dose (mg/kg)	>300	12
MND (14-21 day) C _{max} (ng/mL)	>2908	52
Therapeutic index (14 day)	>10	~2
MND/ED ₅₀ C _{max}		

^a Based on ED₅₀ primary lesion in rat adjuvant arthritis (Table 1) and minimum neurotoxic dose (MND)/plasma C_{max} observed in Spague-Dawley rats ($n = 10$ /dose).

effects were observed. By comparison, tacrolimus showed overt neurotoxic side effects (tremors, convulsions, hyperactivity as measured by a digiscan monitor and death) at oral doses of 12 mg/kg (day 10-14) with an associated plasma drug C_{max} of 52 ng/mL ($n = 3$). In the adjuvant arthritis model, tacrolimus administered at an ED₅₀ dose of 2 mg/kg resulted in a plasma C_{max} of 24 ng/mL ($n = 9$). Calculation of the plasma C_{max} ratio of the minimum neurotoxic dose over the ED₅₀ dose in rat adjuvant arthritis results in a therapeutic index of >10 for compound **1**, whereas tacrolimus has a therapeutic index of ~2. Since the pharmacokinetic properties of the two drugs are very similar, calculations of the therapeutic index using total exposure over 24 h (AUC) gives equivalent toleration ratios. In addition, these results are in accord with the clinical observations of tacrolimus in human transplantation patients.²⁷ A subsequent 30 day rat toxicology study with **1** has recently been conducted as described above. Neurologic toxicities, similar to those observed with tacrolimus were seen with **1** at the median 100 mg/kg dose resulting in a somewhat decreased therapeutic index relative to shorter term studies. As tacrolimus was not included in this study, and the neurotoxic effects of **1** were not dose responsive, a direct comparison of the relative therapeutic indices cannot be determined for the 30 day dosing regimen.

Compound **1** is a macrolactone with efficacy in *in vitro* assays of immune suppression using human T cells and in relevant animal models including rat heart allograft rejection and rat adjuvant arthritis. Of greater importance is the observation that **1** may be less neurotoxic than tacrolimus. Specifically, in 14-21 day experiments in which tacrolimus administration resulted in neurotoxicity as well as mortality, compound **1** showed no toxicity at doses providing equal or greater immunosuppressive activity to that of tacrolimus. Future studies, including longer term experiments, are needed with the prototypic compound to examine this apparent toleration advantage and to help facilitate the search for improved immunosuppressive agents.

Supplementary Material Available: Spectral and physical data for compound **1** and experimental conditions for plasma C_{max} determinations (4 pages). Ordering information is given on any current masthead page.

References

- (1) (a) Calne, R. Y.; Rolles, K.; White, D. J. G.; Thorn, S.; McMaster, P.; Craddock, G. N.; Aziz, S.; Evans, D. B.; Dunn, D. C.; Henderson, R. G.; Lewis, P. Cyclosporin A Initially as the Only Immune Suppressant in 34 Recipients of Cadaveric Organs: 32 Kidneys, 2 Pancreases, 2 Livers. *Lancet* **1979**, 1033. (b) Keeown, P. A. Emerging Indications for the use of Cyclosporin in Organ Transplantation and Autoimmunity. *Drugs* **1990**, *40*, 315-325.

- (2) Hall, B. M. Cells Mediating Allograft Rejection. *Transplantation* **1991**, *51*, 1141–1151.
- (3) Condeelis, J. J. The Autoimmune Diseases. *J. Am. Med. Assoc.* **1992**, *268*, 2882–2892.
- (4) (a) Feutren, G. Clinical Experience with Sandimmune (Cyclosporin) in Autoimmune Diseases. *Transplantation Proceed.* **1990**, *24*, 55–60. (b) Ellis, C. N.; Fradin, M. S.; Messana, J. M.; Brown, M. D.; Siegel, M. T.; Hartley, A. H.; Rocher, L. L.; Wheeler, S.; Hamilton, T. A.; Parish, T. G.; Ellis-Madu, M.; Duell, E.; Annesley, T. M.; Cooper, K. D.; Voorhees, J. J. Cyclosporine for Plaque-Type Psoriasis. *N. Engl. J. Med.* **1991**, *324*, 277–284.
- (5) (a) Silverman, A.; Emmett, M.; Menter, A. Can Maintenance Cyclosporine Be Used in Psoriasis Without Decreasing Renal Function? *Sem. Dermatol.* **1992**, *11*, 302–312. (b) Heering, P.; Schadewaldt, P.; Bach, D.; Grabensee, B. Nephrotoxicity of Cyclosporin in Humans: Effect of Cyclosporin On Glomerular Filtration and Proximal Tubular Reabsorption. *Clin. Invest.* **1993**, *71*, 1010–1015.
- (6) Feutren, G. M.; Hatsch, M. J. Risk Factors for Cyclosporin-Induced Nephropathy in Patients with Autoimmune Disease. *N. Engl. J. Med.* **1992**, *326*, 1654–1660.
- (7) Thiru, S. Pathological Effects of Cyclosporine A in Clinical Practice. In *Cyclosporine: Mode of Action and Clinical Applications*; Thompson, A. W., Ed.; Kluwer Academic Publishers: Dordrecht, 1989; pp 324–364.
- (8) (a) Tanaka, H.; Kuroda, A.; Marasawa, H.; Hataraka, H.; Kiro, T.; Goto, T.; Hashimoto, M.; Taga, T. Structure of FK-506: The Novel Immunosuppressant Isolated from *Streptomyces*. *J. Am. Chem. Soc.* **1987**, *98*, 5031–5033. (b) Peters, D. H.; Fitton, A.; Plosker, G. L.; Foulds, D. Tacrolimus: A Review. *Drugs* **1993**, *46*, 746–794.
- (9) Wilson, J. R.; Eidelman, B.; Abu-Elmagd, K.; Fung, J.; Todo, S.; Van Thiel, D.; Starzl, T. Neurological Complications of FK-506. *Neurology* **1992**, *42* (Suppl. 3), 247S.
- (10) Tzakis, A.; Reyes, J.; Todo, S.; Green, M.; Ohya, T.; Jain, A.; Abu-Elmagd, K.; Alessiani, M.; Fung, J.; Starzl, T. FK-506 Versus Cyclosporine in Pediatric Liver Transplantation. *Transplantation Proceed.* **1991**, *23*, 3010–3015.
- (11) Liu, J. FK-506 and Cyclosporine, Molecular Probes for Studying Intracellular Signal Transduction. *Immunol. Today* **1993**, *14*, 290–295.
- (12) Tocci, M. J.; Matkovich, D. A.; Collier, K. A.; Kwok, P.; Dumont, F.; Lin, S.; Degudicbur, S.; Sverkieka, J. J.; Chin, J.; Hutchinson, N. I. The Immunosuppressant FK-506 Selectively Inhibits Expression of Early T Cell Activation Genes. *J. Immunol.* **1989**, *143*, 718–726.
- (13) Schreiber, S. L.; Crabtree, G. R. The Mechanism of Action of Cyclosporin A and FK-506. *Immunol. Today* **1992**, *13*, 136–142.
- (14) Flanagan, M. W.; Cortesy, B.; Bram, R. J.; Crabtree, G. R. Nuclear Association of a T-Cell Transcription Factor Blocked by FK-506 and Cyclosporin A. *Nature* **1991**, *352*, 803–807.
- (15) (a) Asako, H.; Kabes, P.; Baethge, B. A.; Wolf, R. E.; Granger, D. N. Reduction of Leukocyte Adherence and Emigration by Cyclosporin and FK-506 in Postcapillary Venules. *Transplantation* **1993**, *54*, 686–690. (b) Bishop, D. K.; Li, W. Cyclosporin A and FK-506 Mediate Differential Effects on T Cell Activation *In Vivo*. *J. Immunol.* **1992**, *148*, 1049–1054.
- (16) (a) De Paulis, A.; Cirrillo, R.; Ciccarelli, A.; De Crescenzo, G.; Oriente, A.; Marone, G. Characterization of the Anti-Inflammatory Effect of FK-506 on Human Mast Cells. *J. Immunol.* **1991**, *147*, 4278–4285. (b) Kamitamori, A.; Matsumoto, K.; YoKoo, T.; Hayashi, K.; Tsaji, Y. Effect of FK-506 on Neutrophil Function. 12th Cong. Jpn. Inflamm. Soc. Tokyo. *Abstr.* **84**, 1991. (c) Enlarger, B. E. Do We Know The Site of Action of Cyclosporin? *Immunol. Today* **1992**, *13*, 487–490.
- (17) (a) Sigal, N. H.; Dumont, F.; Durette, P.; Sierkierka, J. J.; Peterson, L.; Rich, D. H.; Dunlap, B. E.; Staruch, M. J.; Melino, M. R.; Koprak, S. L.; Williams, D.; Witzel, B.; Pisano, J. M. In Cyclophilin Involved in the Immunosuppressive and Nephrotoxic Mechanism of Action of Cyclosporin A. *J. Exp. Med.* **1991**, *173*, 619–628. (b) Dumont, F. J.; Staruch, M. J.; Koprak, S. L.; Sierkierka, J. J.; Lin, C. S.; Harrison, R.; Sewell, T.; Kindt, V. M.; Beattie, T. R.; Wyvrat, M.; Sigal, N. H. The Immunosuppressive and Toxic Effects of FK-506 are Mechanistically Related: Pharmacology of a Novel Antagonist of FK-506 and Rapamycin. *J. Exp. Med.* **1992**, *176*, 751–760.
- (18) Paulson, J. C. Glycoproteins: What are the Sugar Chains For? *Trends Biol. Sci.* **1989**, *14*, 272–275.
- (19) Karlsson, K.-A. Glycobiology: a Growing Field for Drug Design. *Trends Pharmacol. Sci.* **1991**, *12*, 265–275.
- (20) Monsigny, M.; Roche, A. C.; Kieda, C.; Midoux, P.; Obrenovitch, A. Characterization and Biological Implications of Membrane Lectins in Tumor, Lymphoid and Myeloid Cells. *Biochemie* **1988**, *70*, 1633–1649.
- (21) (a) Kawai, M.; Lane, B. C.; Hsieh, G. C.; Mollison, K. W.; Carter, G. W.; Luly, J. R. Structure-Activity Profiles of Macrolactam Immunosuppressant FK-506 Analogues. *FEBS Lett.* **1993**, *316*, 107–113. (b) Organ, H. M.; Holmes, M. A.; Pisano, J. M.; Staruch, M. J.; Wyvrat, M. J.; Dumont, F. J.; Sinclair, P. J. Novel Derivatives at the C21 Position of the FK-506 Macrocycles. *Bioorg. Med. Chem. Lett.* **1993**, *4*, 657–662. (c) Furber, M.; Cooper, M. E.; Donald, D. K. Studies Relating to the Immunosuppressive Activity of FK-506. *Tetrahedron Lett.* **1993**, *34*, 1351–1354. (d) Goulet, M. T.; Hodkey, D. W.; Staruch, M. J.; Dumont, F. J.; Cryan, J. G.; Parsons, N. H.; Wyvrat, M. J. Alkyl Ether Analogs of the FK-506 Related Immunosuppressive Macrolide L-683,590 (Ascomycin). *Bioorg. Med. Chem. Lett.* **1994**, *4*, 921–926.
- (22) Kartha, K. P. R.; Jennings, H. J. A Simplified, One Pot of Acetobromosugars from Reducing Sugars. *J. Carbohydr. Chem.* **1990**, *9*, 771–781.
- (23) Okuhara, M.; Horikazu, T.; Goto, T. Tricyclo Compounds, A Process for Their Production and a Pharmaceutical Composition Containing the Same. U.S. Pat. 4894366, 1990.
- (24) Human peripheral blood was separated on Ficoll-Paque (Pharmacia); mononuclear cells were removed from the interface and non-T cells were removed by complement lysis with T-Kwik (One Lambda). Purified T cells (1×10^6 /mL) were stimulated for 2 days with 125 ng/mL ionomycin (Calbiochem) + 5 ng/mL PMA (Sigma). Cells were pulsed with [3 H]thymidine (1 μ Ci/well) (NEN) during the last 18 h of incubation before harvesting. For IL-2 determinations, human mononuclear cells were stimulated for 2 days with 2 μ g/mL PHA (Wellcome) + 10 ng/mL PMA. Supernatants were assayed for IL-2 by ELISA (R & D Systems). Test compounds were added with stimulants in all experiments. The number of experiments are indicated in parentheses.
- (25) Perper, R. J.; Alvarez, B.; Colombo, C.; Schroder, H. The Use of a Standardized Adjuvant Arthritis Assay to Differentiate Between Antiinflammatory and Immunosuppressive Agents. *Proceed. Soc. Exp. Bio. Med.* **1971**, *137*, 506–512.
- (26) Meiser, B. M.; Morris, R. E. The Importance of the Spleen for the Immunosuppressive Action of Cyclosporin in Transplantation. *Transplantation* **1991**, *51*, 690–696.
- (27) Porayko, M. K.; Textor, S. C.; Krom, R. A. F.; Hay, J. E.; Gores, G. J.; Wahlstrom, H. E.; Sanchez-Urdazpal, L.; Richards, T.; Crotty, P.; Beaver, S.; Wiesner, R. H. Nephrotoxicity of FK-506 and Cyclosporin When Used as Primary Immunosuppression in Liver Transplant Recipients. *Transplantation Proceed.* **1993**, *25*, 665–668.

JM940758R